Mindray(SZ:300760) Cai Jing Wang·2025-12-02 09:45Core Viewpoint - The recent share buyback announcement by Mindray Medical (300760.SZ) has attracted significant attention in the capital market, reflecting the confidence of the management team in the company's intrinsic value and future growth prospects [1][5]. Group 1: Buyback Details - On November 27, Chairman Li Xiting initiated a share buyback by purchasing 152,340 shares at an average price of 196.862 CNY per share, totaling approximately 29.99 million CNY [2]. - Li Xiting plans to continue buying back shares over the next six months, with a total investment of 200 million CNY, funded by personal resources, without a fixed price range [2]. - Following the buyback, Li Xiting's direct shareholding increased, and together with his concerted party, they control 51.48% of the company's shares [2]. Group 2: Management Confidence - The buyback activity is part of a broader trend, with multiple senior executives, including Senior Vice President Li Zaiwen and Secretary Li Wenmei, also increasing their holdings, indicating strong internal confidence in the company's future [3][4]. - Li Zaiwen bought 14,700 shares at an average price of 203.52 CNY per share on November 28, while Li Wenmei had previously purchased 5,000 shares at 207.08 CNY per share on November 6 [4]. Group 3: Market Reaction - The announcement of the buyback plan received a positive response from investors, with a notable increase in the stock price by 3.93% to 204.01 CNY per share on November 28, alongside a trading volume of 2.378 billion CNY [5]. - Investors view the buyback as a strong signal of confidence from the management, potentially stabilizing the stock price and providing reassurance to long-term investors [5]. Group 4: Company Performance - Mindray Medical is recognized as a leading domestic medical device company, ranking among the top 30 global medical device firms, with a projected revenue of 36.7 billion CNY in 2024 [5]. - The company has demonstrated robust growth, with a compound annual growth rate (CAGR) of over 18% in revenue and over 24% in net profit from 2017 to 2024, maintaining a return on equity (ROE) and net profit margin above 20% [5].